Fig 1: SLC11A2 mRNA expression in various cancer types. (a) Comparison shows the number of datasets with SLC11A2 mRNA overexpression (left column, red) and under-expression (right column, blue) in cancer compared to normal tissue. This graphical presentation is derived from the Oncomine database, and the thresholds are designed with the following parameters: p-value 1E-4, fold change 2, and gene rank 10%. (b) Expression of SLC11A2 in 33 human cancers by GEPIA2: gene expression profiles of all tumor samples and paired normal tissues displayed as a dot plot. Each point represents the expression of the sample. (c) Expression pattern of SLC11A2 mRNA in tumor and corresponding normal tissues: retrieved from the GENT2 on the expression of SLC11A2 mRNA in various cancers. Boxes represent the median and the 25th and 75th percentiles. Dots represent outliers. The red box represents tumor tissue and the green box represents normal tissue. Statistical methods: two-sample T-test.
Fig 2: SLC11A2 immunohistochemical analysis. (a) Distribution of SLC11A2 protein in 4 tissue types: pathological sections of the normal ovary, normal fallopian tube, ovarian high-grade serous carcinoma, and ovarian carcinoma with omental metastases. Two samples of each tissue type were selected, each sample with two magnifications. (b) The relationship between the expression of SLC11A2 protein in primary ovarian cancer and prognosis (IHC, n = 68). Statistical methods: Cox regression analysis.
Fig 3: Relationship between SLC11A2 and ovarian cancer prognosis; Cell signaling pathway enrichment analysis. (a–d) Kaplan-Mayer PFS curves over high and low SLC11A2 mRNA expression. (f–i) Correlation between SLC11A2 and clinical features of ovarian cancer. (j) Top 10 positively correlated genes with SLC11A2 expression. (k) SLC11A2 co-expressed gene enrichment analysis in ovarian cancer. (Metascape tool).
Fig 4: SLC11A2 knockdown increased cisplatin sensitivity in SKOV3 cell line. (a) Flow cytometry plots of skov3 cells apoptosis. The total amount of apoptosis was early apoptosis plus late apoptosis (right two quadrants). This is a representative plot of 3 independent replicate experiments. (b) Bar graph of percentage apoptosis. Statistical methods: Welch's t-test.
Fig 5: Effects of SLC11A2 knockdown on cell viability and migration. (a) Cell viability treated with cisplatin via CCK8 assay. Statistical methods: independent samples t-test. (b) Image of Transwell migration assay. (NC vs siRNA). (c) Quantification of Transwell migration assay. Statistical methods: independent samples t-test.
Supplier Page from Abcam for Anti-DMT1 antibody